Get the Daily Brief
Latest Biotech News
Labs go autonomous: self-driving materials lab and AI scientist debut
Researchers at the University of Chicago’s Pritzker School developed an autonomous laboratory that can independently produce thin metal films, marrying robotics and AI to accelerate materials...
FSP1 and ferroptosis vulnerabilities: new targets in lung and melanoma
A Nature study identified FSP1 as an essential in vivo survival factor for lung adenocarcinoma, showing that inhibiting FSP1 induces ferroptosis across genetically diverse tumors and exposes a...
Scaling cell therapies: automation, CDMOs and tissue-targeting delivery mapped
Lonza and industry leaders argue that automation and global manufacturing networks are essential to scale CAR T and CAR Treg therapies beyond current bottlenecks, emphasizing early process...
FTC flags Novo’s Metsera offer — deal structure under scrutiny
The Federal Trade Commission told Novo Nordisk and Metsera it has concerns about the structure of Novo’s takeover proposal and whether it sidesteps required premerger review under the...
AI designs antibodies: RFdiffusion achieves atom-level binding
Researchers published Nature results showing RFdiffusion — an AI protein design model — can generate de novo single‑domain antibodies with atomic precision and confirmed binding poses by cryo‑EM....
FDA approves first treatment for TK2 deficiency — UCB’s Kygevvi cleared
The U.S. Food and Drug Administration approved UCB’s KYGEVVI (doxecitine and doxribtimine), the first therapy for thymidine kinase 2 deficiency (TK2d), an ultra‑rare mitochondrial disorder....
Ginkgo wins BARDA award — $22.2M project to scale monoclonal antibody manufacturing
Ginkgo Bioworks secured a contract through BARDA’s BioMaP Consortium worth up to $22.2 million to develop cost‑reducing, scalable approaches for domestic monoclonal antibody (mAb) manufacturing...
Sequencing market shakeup: PacBio revenue slips as Berry wins China clearance
Pacific Biosciences reported a 4% year‑over‑year revenue decline in Q3, missing consensus as instrument sales fell sharply while consumables grew. Management highlighted record consumable revenue...
FDA rejects Biohaven filing — company to cut R&D and reprioritize
The FDA issued a complete response letter (CRL) for Biohaven’s troriluzole (Vyglxia) application in spinocerebellar ataxia, citing concerns with reliance on externally controlled real‑world...
Sarepta’s confirmatory miss rattles Duchenne space — market reacts
Sarepta reported that its confirmatory ESSENCE trial of exon‑skipping antisense oligonucleotide therapies failed to meet the primary endpoint, a result the company attributed in part to...
Braveheart raises $185M — backs HCM challenger from Hengrui
Braveheart Bio closed a $185 million financing to run registration‑enabling studies for a hypertrophic cardiomyopathy (HCM) small‑molecule licensed from Jiangsu Hengrui. Investors include...
Neok Bio debuts with $75M — bispecific ADCs head to IND
Neok Bio launched with a $75 million Series A, backed principally by ABL Bio, to advance two bispecific antibody‑drug conjugates (ADCs) toward IND filings. The Palo Alto startup claims its...
Hepta raises $6.7M to push cfDNA epigenetic test for liver disease
Hepta Bio closed a $6.7 million seed round led by Felicis Ventures and Illumina Ventures to develop an AI‑driven liquid biopsy that analyzes differential methylation in cell‑free DNA for chronic...
FDA rejects Biohaven’s ataxia bid — company to cut R&D
The U.S. Food and Drug Administration issued a complete response letter rejecting Biohaven’s new drug application for troriluzole to treat spinocerebellar ataxia, prompting immediate corporate...
FDA approves UCB’s Kygevvi — first therapy for TK2 deficiency
The FDA approved UCB’s KYGEVVI (doxecitine and doxribtimine) as the first therapy for thymidine kinase 2 deficiency (TK2d), an ultra‑rare, often fatal mitochondrial disease. Approval relied on a...
Metsera bidding war escalates — regulators and rivals push back
Acquisition talks for obesity biotech Metsera have intensified into a high‑stakes bidding war between Novo Nordisk and Pfizer. Novo raised a proposal valuing Metsera at up to $10 billion and...
Sarepta’s Duchenne confirmatory trial misses endpoint — debate erupts
A long‑awaited confirmatory trial for Sarepta’s exon‑skipping therapies failed to meet its primary endpoint. The readout affected Vyondys 53 and Amondys 45 and sent Sarepta shares tumbling;...
AI designs atom‑accurate antibodies — Baker lab validates approach
Researchers led by David Baker refined RFdiffusion to generate de novo, full‑length antibody sequences that bind specified epitopes with atomic precision; cryo‑EM structures confirmed several...
Hepta Bio raises $6.7M to apply cfDNA epigenetics to chronic disease
Hepta Bio closed a $6.7 million seed round led by Felicis Ventures and Illumina Ventures to commercialize an AI‑driven epigenetic analysis of cell‑free DNA for chronic disease detection. The...
Ginkgo wins BARDA award to scale low‑cost mAb manufacturing
Ginkgo Bioworks secured a project agreement through BARDA’s BioMaP Consortium valued up to $22.2 million to develop cost‑reducing, scalable monoclonal antibody manufacturing for filovirus...